SCHEMBL20744489

SCHEMBL20744489

CN1CCN(c2ccc(Nc3ncccn3)nc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCND3 P30281 18/20 0.61
▸ CDK6 Q00534 18/20 0.61
▸ CDK4 P11802 12/20 0.61
▸ CDK9 P50750 11/20 0.61
▸ CCND1 P24385 11/20 0.61
▸ CCNT1 O60563 4/20 0.61
▸ CDK7 P50613 3/20 0.61
▸ CCNH P51946 3/20 0.61
▸ MNAT1 P51948 2/20 0.61
▸ CDK5 Q00535 1/20 0.61
▸ CDK5R1 Q15078 1/20 0.61
▸ CCNK O75909 7/20 0.60
▸ CCNA2 P20248 6/20 0.57
▸ CDK2 P24941 6/20 0.57
▸ CCNE1 P24864 4/20 0.57
▸ CDK1 P06493 3/20 0.55
▸ CCNB1 P14635 2/20 0.53
▸ CCNA1 P78396 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29684118 0.86 CDK6 (0.58) CCND3CDK6CDK4CDK9CCND1
SCHEMBL23296218 0.86 CDK6 (0.58) CCND3CDK6CDK4CDK9CCND1
SCHEMBL30012234 0.85 CDK2 (0.54) CCND3CDK6CDK4CDK9CCND1
SCHEMBL22413899 0.82 CDK4 (0.57) CCND3CDK6CDK4CDK9CCND1
SCHEMBL23296202 0.82 CDK4 (0.64) CCND3CDK6CDK4CDK9CCND1
SCHEMBL4078840 0.80 EGFR (0.60) CDK4CDK2CCNE1
SCHEMBL29557336 0.80 CDK4 (0.59) CCND3CDK6CDK4CDK9CCND1
SCHEMBL16840715 0.80 CCND3 (0.50) CCND3CDK6CDK4CDK9CCND1
SCHEMBL19882691 0.79 CCND3 (0.51) CCND3CDK6CDK4CDK9CCND1
SCHEMBL30541017 0.78 CDK6 (0.62) CCND3CDK6CDK4CDK9CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11351170-B2 Substituted pyrimidines as CDK4/6 inhibitors BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2022-06-07 — — US disclosed
US-20210128555-A1 CDK4/6 INHIBITORS AND USE THEREOF BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2021-05-06 — — US disclosed
WO-2019035008-A1 CDK4/6 INHIBITORS AND USE THEREOF BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11351170-B2 Substituted pyrimidines as CDK4/6 inhibitors CDK4, CDK6, CDK2 CCND3 41/4885CDK6 2/4885CDK4 1/4885
US-20210128555-A1 CDK4/6 INHIBITORS AND USE THEREOF CDK4, CDK6, CDK1 CCND3 38/4885CDK6 2/4885CDK4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback